Nature Communications (Nov 2020)

LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer

  • Qianfeng Shi,
  • Yudong Li,
  • Shunying Li,
  • Liang Jin,
  • Hongna Lai,
  • Yanqing Wu,
  • Zijie Cai,
  • Mengdi Zhu,
  • Qian Li,
  • Ying Li,
  • Jingru Wang,
  • Yujie Liu,
  • Zongqi Wu,
  • Erwei Song,
  • Qiang Liu

DOI
https://doi.org/10.1038/s41467-020-19349-w
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 15

Abstract

Read online

Cyclin D1 is involved in tamoxifen resistance in breast cancer (BC) but how it is regulated is unclear. Here, the authors demonstrate that the LncRNA DILA1 contributes to tamoxifen resistance in breast cancer by binding to Cyclin D1 and preventing its degradation.